Ischemic Stroke Secondary to Atherosclerotic Cerebrovascular Stenosis
Conditions
Interventions
Gold Standard:Primary Endpoints: Recurrence of stroke at 90 days and 1 year post-antiplatelet therapy.
Secondary Endpoint: In-stent restenosis.
Surrogate Endpoint: ADP-induced platelet aggregation rat
Index test:Plasma TMAO, C1q, and C4BPa Concentrations and CYP2C19 Genotyping.
Sponsors
NanJing First Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Age 18-80 years, with ischemic stroke due to atherosclerotic cerebrovascular stenosis; 2.Scheduled for cerebral artery stenting with standard dual antiplatelet therapy (aspirin 100 mg/day + clopidogrel 75 mg/day) for =3 months.
Exclusion criteria
Exclusion criteria: 1.Cardioembolic stroke (e.g., with atrial fibrillation); 2.Embolic stroke of undetermined source (ESUS); 3.erioperative stroke; 4.Requiring intravenous thrombolysis (rt-PA, urokinase, alteplase, or tenecteplase); 5.Mechanical thrombectomy; 6.Current use of anticoagulants (warfarin, rivaroxaban, dabigatran, etc.); 7.Severe hepatic or renal dysfunction; 8.Allergy to clopidogrel or aspirin; 9.Bleeding tendency (e.g., thrombocytopenia or active gastrointestinal ulcer); 10.History of recurrent miscarriage or current pregnancy; 11.Malignancy or life expectancy <1 year.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recurrent stroke;Various vascular ischemic events;Disability;All-cause mortality;Accuracy;Sensitivity;Specificity; | — |
Secondary
| Measure | Time frame |
|---|---|
| ADP-induced platelet aggregation;In-stent restenosis; | — |
Countries
China
Contacts
Public ContactTing Tai
NanJing First Hospital
Outcome results
None listed